Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report

被引:2
|
作者
Zino, Leena [1 ,3 ]
Jacobs, Tom G. [1 ]
Nieuwenstein, Thomas [1 ]
Grintjes, Karin [2 ]
Colbers, Angela [1 ]
Burger, David M. [1 ]
机构
[1] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Pharm, Med Ctr, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Internal Med, Med Ctr, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Pharm, Med Ctr, 864 Radbou dumc,Geert Grooteplein 10, NL-6525 GA Nijmegen, Netherlands
关键词
KIDNEY-FUNCTION; EXPOSURE;
D O I
10.1097/QAD.0000000000003438
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:363 / 365
页数:3
相关论文
共 50 条
  • [31] Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection
    Trang, Tracy P.
    Dong, Betty J.
    Kojima, Noah
    Klausner, Jeffrey D.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (09) : 1287 - 1294
  • [32] Tenofovir disoproxil fumarate associated Fanconi syndrome in an HIV-uninfected man receiving HIV pre-exposure prophylaxis
    Dube, M. P.
    Funk, C. A.
    Corado, K.
    Morris, S.
    [J]. ANTIVIRAL THERAPY, 2016, 21 : A57 - A57
  • [33] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    [J]. HIV MEDICINE, 2020, 21 : 12 - 12
  • [34] Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
    Kojima, Noah
    Klausner, Jeffrey D.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (01):
  • [35] Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France
    Noret, Marion
    Balavoine, Stephanie
    Pintado, Claire
    Siguier, Martin
    Brun, Alexandre
    Bauer, Rebecca
    Loze, Benedicte
    Leplatois, Anne
    Aslan, Alexandre
    Moudachirou, Khafil
    Delaugerre, Constance
    Rozenbaum, Willy
    Molina, Jean-Michel
    [J]. AIDS, 2018, 32 (15) : 2161 - 2169
  • [36] Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women
    Dobkin, April
    McWalters, Jessica
    Barnett, Rebecca
    Ray, Laurie L.
    Espinoza, Lilia
    McGinn, Aileen P.
    Atrio, Jessica M.
    Keller, Marla J.
    [J]. SEXUALLY TRANSMITTED DISEASES, 2020, 47 (12) : 819 - 824
  • [39] Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy
    Roelofsen, Eveline E.
    Wildenbeest, Sieds
    Mollema, Femke P.
    Burger, David M.
    [J]. AIDS, 2020, 34 (13) : 1989 - 1991
  • [40] Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
    Ruane, P. J.
    Clarke, A.
    Post, F. A.
    Schembri, G.
    Jessen, H.
    Trottier, B.
    Bergin, C.
    Molina, J-M
    Wong, P.
    Ebrahimi, R.
    Brainard, D. M.
    Osinusi, A.
    Das, M.
    McCallister, S.
    [J]. HIV MEDICINE, 2019, 20 : 95 - 96